Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 19407849)

1.

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.

Chen GX, Zhang S, He XH, Liu SY, Ma C, Zou XP.

Onco Targets Ther. 2014 Oct 21;7:1901-9. doi: 10.2147/OTT.S50483. eCollection 2014. Review.

2.

ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor.

Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, Korn WM.

Mol Cancer. 2011 Jul 27;10:91. doi: 10.1186/1476-4598-10-91.

3.

A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.

Bagheri N, Shiina M, Lauffenburger DA, Korn WM.

PLoS Comput Biol. 2011 Feb;7(2):e1001085. doi: 10.1371/journal.pcbi.1001085. Epub 2011 Feb 17.

4.

p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.

Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR, McNeish IA.

Mol Cancer. 2010 Jul 3;9:175. doi: 10.1186/1476-4598-9-175.

5.

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Wong HH, Lemoine NR, Wang Y.

Viruses. 2010 Jan;2(1):78-106.

6.

Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.

Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R.

Cancer Gene Ther. 2010 Aug;17(8):585-97. doi: 10.1038/cgt.2010.15. Epub 2010 May 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk